欧林生物股价涨8.48%，华富基金旗下1只基金重仓，持有60万股浮盈赚取126万元

Group 1 - The core point of the article highlights the significant increase in the stock price of Olin Bio, which rose by 8.48% to reach 26.85 CNY per share, with a total market capitalization of 10.893 billion CNY [1] - Olin Bio, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with its main revenue sources being 90.99% from adsorbed tetanus vaccine, 4.49% from group A and C meningococcal polysaccharide conjugate vaccine, and 3.99% from type b Haemophilus influenzae conjugate vaccine [1] Group 2 - From the perspective of fund holdings, Olin Bio is a significant investment for Huafu Fund, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund holding 600,000 shares, representing 7.56% of the fund's net value, making it the fourth-largest holding [2] - The Huafu Health and Entertainment Flexible Allocation Mixed A Fund has achieved a year-to-date return of 12.99% and a one-year return of 42.45%, ranking 539 out of 9009 and 2957 out of 8164 respectively [2]